Oregon Sen. Lisa Reynolds mulls conflict of interest declaration after ethics report
Oregon's statewide ethics watchdog on Thursday referred a Portland-area lawmaker to the Legislature for clarity over whether a bill she authored that could benefit her medical practice raises a substantial conflict of interest.
The Oregon Government Ethics Commission said Sen. Lisa Reynolds' decisions regarding votes and bill introductions were within the purview of the Legislature and its legal counsel, according to a Thursday letter written by Susan Myers, the commission's executive director. Introduced in January, Senate Bill 28 would mandate commercial insurers reimburse independent primary care clinics at rates equal to those of clinics owned by hospital systems.
In the letter, Myers said that Reynolds, D-Portland, 'would be met with a conflict of interest' unless she is able to receive a class exception. The rule is traditionally adjudicated by the commission, determining whether an official action by a public official would impact all members of a 'class,' such as business owners or members of a particular industry, equally.
But it's up to the Legislature, not the Commission, to decide whether the exception applies because the matter 'relates to the performance of legislative functions,' Myers wrote. Lawmakers are allowed to cast votes and perform legislative tasks under Oregon's 'speech and debate' rules for public officials even when they do declare conflicts of interest.
Reynolds told the Capital Chronicle she hasn't decided whether she will seek further advice. She said that she will consult with her staff and tends 'to err on the side of caution.'
'I'll see going forward,' she said. 'It would be interesting to note the votes I've taken. For example, the provider tax which funds Medicaid — do I have to say that's a conflict of interest because my clinic takes Medicaid? I don't think so.'
The advice follows a request from the commission in a May 6 letter written by her chief of staff, Christopher McMorran, a day before the Oregon Journalism Project ran a story in which Reynolds said she was open to seeking the ethics' commissions advice and declaring a conflict of interest.
McMorran sought information about potential conflicts of interest because of Reynolds' job as a primary care provider at The Children's Clinic, an independent clinic in the Portland region.
'SB 28 would likely result in a financial gain for her clinic, along with all other independent primary care clinics in the state,' he wrote to the commission. 'We are curious if her introducing, sponsoring and supporting this bill qualifies as a conflict of interest or if she would be considered a member of a class and be exempt from conflict of interest laws.'
Reynolds said the advice was 'reassuring' and that she believes she would likely qualify for a class exemption.
'I'm a citizen legislator. My day job is that of a pediatrician. In fact, I was in the clinic all last weekend,' she said. 'I still see patients and I actually ran as Dr. Lisa Reynolds. I ran for office leaning into the fact that I am a physician and it informs all that I do in the Legislature.'
Her legislation is currently sitting in the Joint Ways and Means Committee.
SUBSCRIBE: GET THE MORNING HEADLINES DELIVERED TO YOUR INBOX
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
USA Today
a few seconds ago
- USA Today
Marjorie Taylor Greene asks for George Santos' sentence to be commuted
Former New York Republican congressman George Santos began a seven-year federal sentence on charges of wire fraud and aggravated identity theft on July 25. U.S. Rep. Marjorie Taylor Greene is asking President Donald Trump to commute former U.S. Rep. George Santos' prison sentence. Santos, a 37-year-old Republican from New York, reported to the Federal Correctional Institution Flatiron Satellite Camp in New Jersey on Friday, July 25 to begin a seven-year prison sentence for wire fraud and aggravated identity theft. Santos pleaded guilty to the charges last year. Less than two weeks after the disgraced politician's sentence began, Greene, a Republican from Georgia, sent a letter to Pardon Attorney Edward R Martin requesting that he urge the president to take action on the matter. 'I wholeheartedly believe in justice and the rule of the law and I understand the gravity of such actions,' wrote Greene. 'However, I believe a seven-year sentence for such campaign-related matters for an individual with no prior criminal record extends far beyond what is warranted.' Greene continued her letter, stating Santos is 'sincerely remorseful and has accepted full responsibility for his actions.' She alleged: 'Many of my colleagues who I serve with have committed far worse offenses than Mr. Santos yet have faced zero criminal charges.' Newsmax's Rob Finnerty asked the president about intervening in Santos' case in an interview that aired on Friday, Aug. 1. Trump said Santos 'lied like hell,' but 'he was 100 percent for Trump.' Trump said he didn't know Santos and wasn't sure if he had ever met him. While no one specifically asked him to intervene in the case, the president agreed that seven years is 'a long time.' He didn't rule out the possibility of commuting Santos' sentence, telling Finnerty: 'I have the right to do it.' In his second administration, Trump's already granted 58 pardons and 12 commutations. On the president's first day in office, he granted clemency to every person charged or convicted for their role in the Jan. 6, 2021 attack on the U.S. Capitol. More recently, he pardoned reality TV stars Julie and Todd Chrisley. The couple was convicted of fraud and tax evasion in 2022. Their daughter, Savannah Chrisley, has been a staunch Trump supporter and endorsed the president in a speech at the 2020 Republican National Convention. Shortly after Santos won the New York Third Congressional District election in 2022, media outlets discovered he had lied about much of his past, including a career on Wall Street, connections to the Holocaust and the Sept. 11 attacks. Parts of his resume also were called into question. In December 2023, he was expelled by his fellow congressional members. Santos had a history of advocating for the president's agenda and found himself aligned with other lawmakers who shared similar ideals, including Greene. Shortly after arriving in prison, Santos wrote an op-ed for The South Shore Press, a Long Island, New York-area newspaper, which was published on Monday, Aug. 4. 'As I crossed the threshold of the dormitory and took my first steps into what would become my new reality, I caught a glimpse of myself in the small, scratched mirror held up by one of the inmates,' wrote Santos. 'That image – me, hollow-eyed, clad in state-issued polyester – hit me like a punch to the gut.' Michelle Del Rey is a trending news reporter at USA TODAY. Contact her at mdelrey@
Forbes
a minute ago
- Forbes
A System Wide Diagnosis For America's $5 Trillion Healthcare Problem
From the passage of the One Big Beautiful Bill to CMS's newly announced strategic direction, from executive orders on pharmaceutical pricing to ongoing scrutiny of PBMs, Medicaid and the 340B program, there's no shortage of movement across the healthcare landscape. At first glance, these efforts may seem disconnected. Actually, they reflect a growing recognition of a system-wide problem: the incentives that govern our healthcare system are broken. Fixing them requires more than incremental change. If we're serious about delivering better health outcomes at lower cost, we must embrace a new business model, one that aligns incentives, promotes transparency and holds every stakeholder accountable for the value it provides. Each segment of the healthcare ecosystem–payers, providers, PBMs and pharmaceutical companies–is operating from its own silo, maximizing its share of the revenue pie without regard to outcomes or long-term sustainability. That siloed behavior is a fundamental flaw in a sector that now costs the United States $4.9 trillion annually. The result is a system that punishes reform and rewards inefficiency. Hospitals expand expensive outpatient facilities to maintain margins. Insurers make money by denying claims. PBMs chase rebates that inflate drug costs. And pharmaceutical manufacturers operate in a reimbursement landscape that discourages the use of cheaper generic and biosimilar drugs. Even 340B, originally intended to serve vulnerable populations, has become a revenue tool divorced from its original purpose. We can't keep patching a system that was never designed to deliver value. Now is the time to step back and evaluate how all the pieces interact and redesign the model accordingly. The healthcare delivery system revolves around a business model that puts volume over outcomes. That underlying structure remains largely intact despite numerous tweaks and new initiatives over the years. CMS's new strategy emphasizes accountability and site-neutral payment, both necessary steps toward rationalizing where and how care is delivered. But change cannot stop at policy guidance. Provider organizations must take the next step by investing in models that focus on results, not just compliance. That means rethinking how care is delivered, particularly in rural and underserved areas. As I wrote in a May column, rural hospitals cannot survive under today's centralized, hospital-centric model. We need a distributed, tech-enabled system that integrates clinics, pharmacies and telemedicine in a tiered structure. It also means providers must be held to evidence-based standards and be willing to compete based on performance. The government's job is to set expectations, not to micromanage care. Payers likewise need a reset. Trust in insurers is at historic lows. And it's more than a PR problem; it's a structural one. The traditional payer model is built on controlling costs by restricting access. Prior authorization, step therapy and opaque coverage decisions have become tools of denial rather than value management. As I noted in a February column, insurers need to move from gatekeepers to health partners. That shift requires transparency, consistent communication and a willingness to align financial incentives with long-term health outcomes. Some companies have taken early steps, like reducing prior authorization for high-performing providers, but these efforts remain too narrow. Utilization management should focus resources where scrutiny is needed, instead of imposing blanket barriers. When done right, insurers can reward evidence-based, cost-effective care while simplifying the patient experience. Ultimately, payers that adopt a value-based model will be most likely to remain profitable. Those that cling to denial-based cost control will lose both trust and relevance. The dysfunction in drug pricing is no secret. PBMs, originally intended to negotiate better prices, now profit from opaque rebate structures that reward high list prices and block competition from lower-cost alternatives. As I detailed in a recent column, this model harms consumers, distorts prescribing behavior and inflates costs without improving access or outcomes. It's no coincidence that generics, despite comprising nearly 90% of prescriptions, account for only a small fraction of total drug spending. The system must be redesigned to reward clinical and economic value instead of volume. That means eliminating rebate-driven incentives, mandating transparency and tying formulary placement to outcomes rather than backroom deals. PBM reform must be part of a broader effort to move the entire pharmaceutical supply chain towards value-based principles. This includes making sure manufacturers are reimbursed appropriately for true innovation, while allowing low-cost generics and biosimilars to compete on fair terms. Lastly, Medicare, Medicaid and programs like 340B are essential to supporting vulnerable populations, but they can't be immune from scrutiny. We spend more than enough on public healthcare. The problem is how that money is used. As I argued in July, Medicaid in particular has become a proxy for universal coverage without addressing the underlying inefficiencies that drive cost. Meanwhile, 340B, originally a limited safety-net program, has ballooned into a multi-billion-dollar revenue stream for hospitals, often with little connection to actual indigent care. CMS's new strategic direction is a promising departure from past approaches. By linking payment models to cost and outcomes, it opens the door to meaningful change. But success will require the agency to stay focused on results. Accountability must be built into every public dollar spent, from reimbursement to subsidies to drug pricing. Without it, reform is impossible. In the American healthcare ecosystem, each stakeholder is doing what the current model rewards, to the detriment of patients and taxpayers. Funding patches and other temporary solutions can't fix it. We need a fundamentally different business model, one grounded in outcomes, transparency and competition. Each player must change the way they operate and be willing to take responsibility for creating and communicating value. With a better business model, we can have better results for patients, taxpayers and companies. The path forward isn't easy. But it is clear.
Yahoo
29 minutes ago
- Yahoo
Michigan Gov. Whitmer makes another White House visit to meet with Trump
WASHINGTON (AP) — Michigan Gov. Gretchen Whitmer met with President Donald Trump at the White House on Tuesday to discuss the toll tariffs are taking on the auto industry and the potential effects of his tax and spending bill on Medicaid. It's the latest in a string of meetings between the Democratic governor and the Republican president after the two frequently clashed during his first term. In his second term, Whitmer has adopted a more diplomatic approach, drawing some backlash from fellow Democrats. But it's also resulted in multiple wins for Whitmer's state, including Trump's approving $50 million in storm relief and awarding a new fighter jet mission for an Air National Guard base in the state. 'I've always said that I'll work with anyone to get things done for Michigan,' Whitmer, a potential 2028 presidential candidate, said in a statement Tuesday. 'That's why I've continued to go to Washington, D.C., to make sure that Michiganders are front and center when critical decisions are being made.' The private meeting between Whitmer and Trump — which a White House official would not confirm but did stress Trump's continued focus on Michigan — marks a rare instance of the president sitting with a leading Democratic figure. In recent weeks, Trump attacked Senate Democratic leader Chuck Schumer, telling him to 'go to hell," while also taking aim at other high-profile Democratic governors who have pushed back on some of his policies, including California's Gavin Newsom and Illinois' JB Pritzker, also considered possible 2028 candidates. Pritzker has aided Texas Democrats in leaving their state to stay in Illinois to block Republicans from their needed quorum to pass a new congressional map backed by Trump. Early Tuesday, Trump called Pritzker 'probably the dumbest of all governors' in a television interview. Whitmer has been more careful, criticizing some of Trump's policies rather than the president himself. She issued an executive directive last week to assess the impact of tariffs that she said have led to 'massive economic uncertainty' — without mentioning Trump's name once. Tuesday's appearance ended with far less controversy than her trip to the White House in April. Whitmer was unexpectedly ushered into the Oval Office during that visit, standing awkwardly nearby as the Republican president signed executive orders and assailed his political opponents during a photo opportunity. In their White House meeting Tuesday, Whitmer said that she told Trump and 'his team about the impact tariffs are having on Michigan's economy, especially our auto industry.' She also discussed 'changes in the Medicaid program, and ongoing recovery efforts following the ice storm in Northern Michigan this year." Whitmer also saw Secretary of State Marco Rubio, Defense Secretary Pete Hegseth and chief of staff Susie Wiles while at the White House. Trump announced last month that he had spoken with Whitmer to inform her that he was appproving $50 million in federal funds for Michigan to support repairs and recovery from a March ice storm. In April, Trump traveled to Michigan to announce a new mission for Selfridge Air National Guard Base, which Whitmer has sought for years.
